Navigation Links
Nanoparticles help Mayo Clinic researcher deliver steroids to retina
Date:12/13/2011

ROCHESTER, Minn. -- Hitching a ride into the retina on nanoparticles called dendrimers offers a new way to treat age-related macular degeneration and retinitis pigmentosa. A study by investigators at Mayo Clinic, Wayne State University and Johns Hopkins Medicine shows that steroids attached to the dendrimers target the damage-causing cells associated with neuroinflammation, leaving the rest of the eye unaffected and preserving vision. The findings appear in the journal Biomaterials.

Dry age-related macular degeneration and retinitis pigmentosa are caused by neuroinflammation, which progressively damages the retina and can lead to blindness. Macular degeneration is the primary cause of vision loss in older Americans, affecting more than 7 million people, according to the National Institutes of Health. Retinitis pigmentosa encompasses many genetic conditions affecting the retina and impacts 1 in 4,000 Americans, the NIH estimates.

"There is no cure for these diseases," says Mayo Clinic ophthalmologist Raymond Iezzi, M.D., a lead author of the study. "An effective treatment could offer hope to hundreds of millions of patients worldwide."

Iezzi and fellow principal author Rangaramanujam Kannan, Ph.D., an ophthalmology professor at The Wilmer Eye Institute of Johns Hopkins, developed an intracellular, sustained-release drug delivery system. The research, conducted in part at Wayne State University's Kresge Eye Institute with collaboration from Wayne State's College of Engineering and Ligon Research Center of Vision, tested the dendrimer delivery system in rats that develop neuroinflammation.

The target was microglial cells, inflammatory cells in charge of cleaning up dead and dying material in the eye, Dr. Iezzi says. When activated as "trash collectors," the cells cause damage via neuroinflammation -- a hallmark of each disease. The microglial cells gobble up the dendrimers, and the drug then shuts down the cells' activity.

"Surprisingly, the activated microglia in the degenerating retina appeared to eat the dendrimer selectively, and retain them for at least a month. The drug is released from the dendrimer in a sustained fashion inside these cells, offering targeted neuroprotection to the retina," Kannan says.

The treatment reduced neuroinflammation in the rat model and protected vision by preventing injury to photoreceptors in the retina. Though the steroid offers only temporary protection, the treatment as a whole provides sustained relief from neuroinflammation.


'/>"/>

Contact: Robert Nellis
newsbureau@mayo.edu
507-284-5005
Mayo Clinic
Source:Eurekalert

Related medicine news :

1. Nanoparticles help researchers deliver steroids to retina
2. New device uses gold nanoparticles to test for lung cancer
3. Study indicates nanoparticles could help pain-relieving osteoarthritis drugs last longer
4. Consumers close encounters with nanoparticles
5. UGA researchers use gold nanoparticles to diagnose flu in minutes
6. Gold nanoparticles bring scientists closer to a treatment for cancer
7. Gold nanoparticles help earlier diagnosis of liver cancer
8. Nanoparticles disguised as red blood cells will deliver cancer-fighting drugs
9. Research creates nanoparticles perfectly formed to tackle cancer
10. Good cholesterol nanoparticles seek and destroy cancer cells
11. Research provides new findings on drug delivery with nanoparticles
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... April 29, 2016 , ... The American workforce is ... even security. Most importantly, employees are the single most important asset in creating ... so unhappy? , Just under half of American workers are emotionally checked out ...
(Date:4/29/2016)... , ... April 29, 2016 , ... Coast Dental Fort ... 2016, at its new location in the Exchange Furniture Mall at 112 Vilseck Road ... a 50-inch Samsung Smart TV. Plus attendees will have the opportunity to meet general ...
(Date:4/29/2016)... ... , ... Mobility Designed is redefining mobility with their patent pending crutch ... evenly distributes body weight from the elbow to the forearm. In consumer tests, ... with other crutches. , Co-founders Max and Liliana Younger were inspired to design the ...
(Date:4/29/2016)... ... ... Dr. Robert Mondavi, one of the dentists in Torrance , is ... field as more patients are discovering the many different ways they can change and ... available to them and which ones might work for their smiles. , “One ...
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... ... closing of a growth round of funding led by Eastside Partners, with participation ... the company’s rapidly growing customer base and accelerate its technology and product roadmap. ...
Breaking Medicine News(10 mins):
(Date:4/27/2016)... April 27, 2016   ... Growth in Recurring Consumable Sales  Clinical sales ... Kea Technologies (Euronext: MKEA, OTCQX: MKEAY) inventor of Cellvizio®, ... sales for the first quarter ended March 31, 2016 ... execution of its commercial strategy. First Quarter ...
(Date:4/27/2016)... Tie-up with Government hospitals as ... to save newborns   Fortis La Femme, ... collaboration with Breast Milk Foundation (BMF), a non-profit organization within ... Bank, ,Amaara, in Delhi-NCR today. This non-profit centre recognizes that ... and should be available to babies deprived of mother,s milk.  ...
(Date:4/27/2016)... 2016 Oasmia Pharmaceutical AB ... a new generation of drugs within human and ... for Paclical/Apealea in the Phase III study that ... ovarian cancer. These preliminary results showed non-inferiority between ... carboplatin versus Taxol in combination with carboplatin. In ...
Breaking Medicine Technology: